- This event has passed.
Early Payer / HTA Consultation Informing Your Global Market Access Strategy
The benefits of undertaking Scientific Advice early in the Market Access process for a new product
Early Health Technology Assessment (HTA) consultation can be valuable in terms of reducing the overall go-to-market risk associated with new pharmaceutical, medical device or diagnostic products. Specifically, early HTA scientific advice supports manufacturers in optimising their product development programme to generate evidence that is relevant for health technology assessors, payers and regulators.
Scientific advice has gained momentum globally over recent years and many processes have evolved. This Mapi symposium will present the value of early engagement from the payer, HTA and industry perspectives. This event will provide the audience with an overview of European processes and the insights gained from experience of the NICE, G-BA and HAS scientific advice processes, including parallel HTA-regulatory scientific advice. Experts will be in attendance to exchange views and answer questions.